Last $15.13 USD
Change Today -0.12 / -0.79%
Volume 392.0K
THRX On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$15.23
Previous Close
$15.25
Day High
$15.84
Day Low
$15.03
52 Week High
02/19/14 - $32.88
52 Week Low
11/11/14 - $12.78
Market Cap
1.7B
Average Volume 10 Days
739.6K
EPS TTM
$-1.45
Shares Outstanding
115.4M
EX-Date
11/21/14
P/E TM
--
Dividend
$1.00
Dividend Yield
3.30%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

241 Employees
Last Reported Date: 03/3/14
Founded in 1996

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.4K
Compensation as of Fiscal Year 2013.

theravance inc (THRX) Key Developments

Theravance Seeks Acquisitions

Theravance Inc. (NasdaqGS:THRX) will consider acquisitions. Mike Aguiar, President and Chief Executive Officer said, "We are hoping to be looking at acquiring additional assets over time to address the terminal value and the long-term nature of the business, but again that really is probably the last of the priorities where we stand today."

Theravance Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:15 PM

Theravance Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:15 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Mathai Mammen.

Theravance Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:35 AM

Theravance Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:35 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Michael W. Aguiar, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $15.13 USD -0.12

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $13.84 USD -0.33
Nektar Therapeutics $16.67 USD -0.04
Progenics Pharmaceuticals Inc $6.96 USD -0.27
Sucampo Pharmaceuticals Inc $11.72 USD -0.21
Synergy Health PLC 2,020 GBp +60.00
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 604.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 281.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.theravance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.